HUB Organoids Launches IntegriGut Screen: A Breakthrough Service Offering for Inflammatory Bowel Disease (IBD) Drug Discovery and Development
HUB Organoids official news RSS · 行业原文收录 · 来源发布：Wed Jan 24 2024 17:36:01 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
已保存的原文节选
Utrecht, Netherlands – 25th Jan 2024 – HUB Organoids (HUB), a global leader and sole proprietor of patient-derived organoid technology for drug discovery and development, today announced the global launch of its new IntegriGut Screen. This innovative screening service employs IBD patient-derived organoid monolayers (PDO Monolayers) allowing access to high-quality human data on epithelial barrier [
以上为带出处的原文节选，完整内容请阅读原始链接。自动收录与主题分类不等于事实核验。